Navigation Links
Serina Therapeutics Announces Agreement Retaining Woodside Capital Partners as Advisor and Investment Bank

HUNTSVILLE, Ala., April 18, 2013 /PRNewswire/ -- Serina Therapeutics, Inc., a pharmaceutical research and development company that has developed a proprietary, patented polymer technology for drug development based upon poly(oxazoline) - POZ, announced today that the company has entered into a definitive agreement with Woodside Capital Partners retaining them as the Company's advisor and investment bank. The details of the agreement were not disclosed.

"We are very pleased to announce that Serina Therapeutics has reached an agreement to have Woodside Capital Partners serve as our advisor and investment bank. Woodside Capital and its elite group of partners and life science advisors have a remarkable track record of helping to create shareholder value in promising biotechnology companies," said Randall Moreadith , MD, PhD, President and Chief Executive Officer of Serina. "Now that we are beginning to move our first clinical candidate toward Phase I in early 2014, and have signed an alliance with a large pharmaceutical partner for development of a POZ-therapeutic, we felt it was time to bring in an expert in doing deals across a wide range of companies in the pharmaceutical industry. We think Woodside Partners fills that need exceptionally well."

"Woodside Capital looks forward to working with the seasoned management team and board at Serina to complete additional transactions with selected pharmaceutical partners," said John Selig , Managing Director and co-head of Woodside Capital's Life Sciences Group. "We believe Serina's POZ technology has the potential to significantly improve the product profile of a large number of molecules across therapeutic areas."

About Serina

Serina Therapeutics is a privately held pharmaceutical company located at the Hudson-Alpha Institute for Biotechnology in Huntsville, AL that develops novel polymer therapeutics based on its proprietary poly(oxazoline) (POZ) technology platforms.  The founders and managers of Serina were formerly the key principals of Shearwater Polymers, a company that enabled twelve approved polyethylene glycol (PEG) products for various pharmaceutical partners.  Besides developing its own pipeline of pharmaceutical products for Parkinson's disease and cancer, Serina is also partnering its technology with pharmaceutical companies to develop high value products addressing unmet clinical needs.  

For more information on Serina Therapeutics, please visit

About Woodside Capital Partners

Woodside Capital Partners is a global investment bank with offices in Silicon Valley and London that delivers world-class strategic and financial advice to emerging growth companies in the life sciences and technology sectors. With a strong track record in strategic partnerships, M&A and private placements, Woodside Capital has been providing investment banking services worldwide since 2001 with leading domain experience in life sciences, software, Internet services, electronic communications and materials.  The team of Woodside Capital has completed transactions totaling more than $10 billion.  The firm is also the Silicon Valley headquarters of M&A International, the world's leading mergers and acquisitions alliance.  

For more information on Woodside Capital, please visit

SOURCE Serina Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Serina Therapeutics Announces Worldwide Exclusive License Agreement with The Scripps Research Institute for Click Chemistry
2. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
3. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
4. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
5. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
6. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
7. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
8. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
9. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
10. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
11. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
Post Your Comments:
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced ... as its e-clinical software solution of choice.  This ... best possible value to their clients by offering ... The preferred relationship establishes nowEDC as the EDC ... for MedSource,s full-service clients.  "nowEDC has long been ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... Kasmer, a legally blind and certified personal trainer is helping to develop a weight loss ... plans to fix the two major problems leading the fitness industry today:, ... , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
Breaking Medicine News(10 mins):